PureTech Health's Seaport Therapeutics Announces Publication Of First-In-Human Clinical And Preclinical Data For GlyphAllo In Science Translational Medicine

PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the publication of first-in-human clinical and preclinical data for GlyphAllo™ (SPT-300 or Glyph Allopregnanolone) in Science Translational Medicine.The GlyphAllo program and the underlying Glyph platform were initially advanced at PureTech, applying the Company's strategy of identifying clinically validated pharmacology and overcoming key limitations through targeted innovation. The Glyph platform and related programs are now being advanced by PureTech's Founded Entity, Seaport Therapeutics.The full text of the announcement from Seaport is as follows:Seaport Therapeutics Announces Science Translational Medicine Peer-Reviewed Publication Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in HumansNewly published findings further support clinical validation of Seaport's proprietary Glyph™ platform to enable oral dosingData supported advancement of ongoing Phase 2b clinical trial of GlyphAllo in major depressive disorder (MDD)BOSTON, March 25, 2026 – Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders with a proven strategy and team, today announced the first comprehensive disclosure of first-in-human clinical and preclinical data for GlyphAllo™ (SPT-300 or Glyph Allopregnanolone), a novel, Glyphed oral prodrug of allopregnanolone, published in Science Translational Medicine, tracing the program's pathway from discovery through initial proof-of-concept. The peer-reviewed article, titled "An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans," details the design, optimization, and clinical translation of GlyphAllo, and further supports clinical validation of Seaport's proprietary Glyph™ platform.